ID Source | ID |
---|---|
PubMed CID | 15766 |
CHEMBL ID | 3185325 |
SCHEMBL ID | 754914 |
MeSH ID | M0098394 |
Synonym |
---|
9frh35yh8r , |
unii-9frh35yh8r |
4-06-00-01643 (beilstein handbook reference) |
pentachloromethylthiobenzene |
methyl pentachlorophenyl sulfide |
pentachlorophenyl methyl sulfide |
methylthiopentachlorobenzene |
sulfide, methyl pentachlorophenyl |
pctas |
pentachlorothioanisole |
benzene, pentachloro(methylthio)- |
hsdb 4326 |
brn 2214412 |
pentachloro(methylthio)benzene |
einecs 217-363-8 |
1,2,3,4,5-pentachloro-6-methylsulfanylbenzene |
inchi=1/c7h3cl5s/c1-13-7-5(11)3(9)2(8)4(10)6(7)12/h1h3 |
lgzzjtiuejnnkv-uhfffaoysa- |
1,2,3,5,6-pentachloro-4-(methylthio)benzene |
1825-19-0 |
P1067 |
NCGC00248177-01 |
dtxcid1022263 |
NCGC00254713-01 |
tox21_300809 |
dtxsid3042263 , |
cas-1825-19-0 |
methyl-pentachlorophenylsulfide |
FT-0633862 |
pentachlorophenyl methyl sulfide [hsdb] |
benzene, 1,2,3,4,5-pentachloro-6-(methylthio)- |
SCHEMBL754914 |
LGZZJTIUEJNNKV-UHFFFAOYSA-N |
1,2,3,4,5-pentachloro-6-(methylsulfanyl)benzene |
CHEMBL3185325 |
AKOS028108388 |
mfcd00013622 |
methyl-pentachlorophenylsulfide, pestanal(r), analytical standard |
AS-66967 |
methyl pentachlorophenylsulfide 100 microg/ml in cyclohexane |
methyl pentachlorophenylsulfide 10 microg/ml in cyclohexane |
methyl pentachlorophenylsulfide |
J-011679 |
methyl(perchlorophenyl)sulfane |
Q27272502 |
T71975 |
BAA82519 |
CS-0324120 |
Excerpt | Relevance | Reference |
---|---|---|
" Biliary metabolites from rats dosed with pentachlorothioanisole (PCTA) were characterized by fast atom bombardment mass spectrometry and electron impact mass spectrometry." | ( Biliary excretion and intestinal metabolism in the intermediary metabolism of pentachlorothioanisole. Bakke, JE; Feil, VJ; Mulford, DJ, 1990) | 0.28 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 54.6118 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 26.3827 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 15.3917 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 38.6622 | 0.3758 | 27.4851 | 61.6524 | AID743217 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 68.1713 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 48.6728 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 32.1647 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895; AID1259395 |
activating transcription factor 6 | Homo sapiens (human) | Potency | 57.9436 | 0.1434 | 27.6121 | 59.8106 | AID1159516; AID1159519 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 54.6118 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 41.5652 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 68.1713 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 61.2754 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 19.2133 | 0.0006 | 27.2152 | 1,122.0200 | AID743202 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 76.4895 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (20.00) | 18.7374 |
1990's | 7 (35.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 8 (40.00) | 24.3611 |
2020's | 1 (5.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.48) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (5.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 19 (95.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |